Drug-Induced Liver Injury

Idiosyncratic liver injury associated with drugs (ILIAD)

Enrollment status: OPEN

The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin®), amoxicillin/clavulanate (Augmentin®), minocycline, nitrofurantoin, trimethroprim/sulfamethoxazole (Bactrim®), or valproic acid (Depakote®), after January 1, 1994. This study is funded by the NIH/NIDDK.

Study design

Contacts for referrals or questions: see below

A multi-center, longitudinal study of drug-induced and complementary and alternative medication—induced liver injury

Enrollment Status: OPEN

The goal of this multicenter NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.

Study Design


Contacts for referrals or questions:

Principal Investigator: Robert Fontana, MD rfontana@med.umich.edu

For more information on drug-induced liver injury, see the following web sites:

Drug-Induced Liver Injury Network: http://dilin.dcri.duke.edu/index.html

NIH funds network to study drug-induced liver injury: http://www.nih.gov/news/pr/nov2004/niddk-19.htm

NIDDK LiverTox web site: http://www.livertox.nih.gov/